Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815574) titled 'iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Scancell Ltd
Condition:
Melanoma (Skin Cancer)
Advanced Melanoma
Metastatic Melanoma
Skin Cancer
Intervention:
Biological: iSCIB1+
Drug: Nivolumab & Ipilimumab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 1, 2026 ...